• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Deterioration of the liver biochemistry due to reactivation of chronic hepatitis B during etanercept treatment for rheumatoid arthritis.类风湿关节炎患者在接受依那西普治疗期间，慢性乙型肝炎再激活导致肝脏生化指标恶化。
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.09.2008.0873. Epub 2009 Mar 17.
2
Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.HBV 核心抗体阳性的类风湿关节炎患者接受抗 TNF-α 治疗时病毒载量的动力学变化及乙型肝炎病毒再激活的风险。
Ann Rheum Dis. 2011 Oct;70(10):1719-25. doi: 10.1136/ard.2010.148783. Epub 2011 Jun 29.
3
Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice.在乙肝病毒携带者状态的类风湿关节炎患者中，停用抗病毒预防措施与乙肝病毒（HBV）再激活的高发生率相关：一项真实世界临床实践。
BMC Musculoskelet Disord. 2014 Dec 22;15:449. doi: 10.1186/1471-2474-15-449.
4
Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.使用阿巴西普治疗期间隐匿性乙型肝炎病毒感染再激活：一例报告
BMC Pharmacol Toxicol. 2016 Apr 21;17:17. doi: 10.1186/s40360-016-0060-2.
5
Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.短期托珠单抗增加类风湿关节炎患者乙型肝炎病毒再激活风险：一项前瞻性临床观察
Int J Rheum Dis. 2017 Jul;20(7):859-869. doi: 10.1111/1756-185X.13010. Epub 2017 Feb 3.
6
Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.血液系统恶性肿瘤患者在完成细胞毒性化疗后停用抢先使用的拉米夫定后发生的乙型肝炎再激活。
Gut. 2005 Nov;54(11):1597-603. doi: 10.1136/gut.2005.070763. Epub 2005 Jul 6.
7
Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.接受生物性改善病情抗风湿药物治疗的类风湿关节炎患者中，已缓解的乙型肝炎病毒再激活的发生率及危险因素。
Int J Rheum Dis. 2019 Apr;22(4):574-582. doi: 10.1111/1756-185X.13401. Epub 2018 Oct 18.
8
Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases.抗 TNF-α 药物治疗的类风湿关节炎和强直性脊柱炎患者乙型肝炎病毒再激活：49 例回顾性分析。
Clin Rheumatol. 2012 Jun;31(6):931-6. doi: 10.1007/s10067-012-1960-1. Epub 2012 Feb 17.
9
Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients.类风湿关节炎患者乙型肝炎病毒复制再激活的流行情况。
Mod Rheumatol. 2011 Feb;21(1):16-23. doi: 10.1007/s10165-010-0337-z. Epub 2010 Jul 29.
10
Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.类风湿关节炎患者接受利妥昔单抗治疗时，HBsAg阴性/HBcAb阳性患者乙肝病毒再激活的发生率及临床特征
Clin Exp Rheumatol. 2017 Sep-Oct;35(5):831-836. Epub 2017 Mar 31.

引用本文的文献

1
Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.与抗风湿治疗相关的乙型肝炎病毒再激活：风险及预防建议。
World J Gastroenterol. 2015 Sep 28;21(36):10274-89. doi: 10.3748/wjg.v21.i36.10274.

本文引用的文献

1
Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.肿瘤坏死因子-α抑制剂在慢性乙型肝炎感染患者中的应用。
Semin Arthritis Rheum. 2008 Dec;38(3):208-17. doi: 10.1016/j.semarthrit.2007.10.011. Epub 2008 Jan 25.
2
Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach.乙型和丙型肝炎病毒感染与抗肿瘤坏死因子-α治疗：临床处理指南
J Gastroenterol Hepatol. 2006 Sep;21(9):1366-71. doi: 10.1111/j.1440-1746.2006.04559.x.
3
Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.风湿性疾病中免疫抑制治疗导致的乙型肝炎病毒（HBV）再激活：评估与预防策略
Ann Rheum Dis. 2006 Aug;65(8):983-9. doi: 10.1136/ard.2005.043257. Epub 2006 Apr 20.
4
Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.类风湿关节炎和脊柱关节病合并慢性B或C型肝炎时抗TNF-α治疗的安全性
Rheumatology (Oxford). 2006 Oct;45(10):1294-7. doi: 10.1093/rheumatology/kel123. Epub 2006 Apr 7.
5
Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?英夫利昔单抗治疗克罗恩病后出现亚急性重型乙型肝炎：是否需要进行乙肝病毒筛查？
World J Gastroenterol. 2006 Feb 14;12(6):974-6. doi: 10.3748/wjg.v12.i6.974.
6
Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy.在使用英夫利昔单抗治疗重度脊柱关节病期间，潜伏性前核心突变型乙型肝炎病毒相关慢性肝炎的再激活。
Ann Rheum Dis. 2005 May;64(5):788-9. doi: 10.1136/ard.2004.031187.
7
Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.英夫利昔单抗治疗克罗恩病患者后发生慢性乙型肝炎再激活：需要进行一级预防。
Gut. 2004 Sep;53(9):1363-5. doi: 10.1136/gut.2004.040675.
8
Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.英夫利昔单抗用于慢性乙型或丙型肝炎患者的风湿性疾病治疗。
J Rheumatol. 2004 Jan;31(1):107-9.
9
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.肿瘤坏死因子抑制剂治疗类风湿关节炎可能会使结核病风险显著增加：一项多中心主动监测报告。
Arthritis Rheum. 2003 Aug;48(8):2122-7. doi: 10.1002/art.11137.
10
Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.英夫利昔单抗治疗一名患有成人起病型斯蒂尔病的乙肝病毒感染者后出现暴发性肝炎
J Rheumatol. 2003 Jul;30(7):1624-5.

类风湿关节炎患者在接受依那西普治疗期间，慢性乙型肝炎再激活导致肝脏生化指标恶化。

Deterioration of the liver biochemistry due to reactivation of chronic hepatitis B during etanercept treatment for rheumatoid arthritis.

作者信息

Kuo Shu-Chen, Lee Hui-Ting, Chen Wei-Sheng, Chou Chung-Tei, Tsai Chang-Youh

机构信息

Taipei Veterans General Hospital, Division of Allergy, Immunology & Rheumatology, 201 Shih-Pai Road Section 2, Taipei, 112, Taiwan, Province of China.

出版信息

BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.09.2008.0873. Epub 2009 Mar 17.

DOI:10.1136/bcr.09.2008.0873
PMID:21686590
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3029840/
Abstract

To report a hepatitis B virus (HBV) reactivation during the treatment of etanercept for rheumatoid arthritis (RA).The chronological course of a patient with RA who developed HBV reactivation associated with etanercept treatment was recorded.A Taiwanese woman with RA was treated by etanercept. A severe deterioration of liver biochemistry occurred soon after the start of the biologicals because of the previously unrecognised HBV carrier status. The condition was successfully alleviated by oral lamivudine administration.In the prevalent area of HBV, viral titre monitoring and pre-emptive antiviral treatment may be fundamentally important to avoid serious complications of HBV reactivation whenever a new treatment modality such as biologicals is started for patients with RA.

摘要

报告类风湿关节炎（RA）患者在使用依那西普治疗期间发生的乙型肝炎病毒（HBV）再激活。记录了一名发生与依那西普治疗相关的HBV再激活的RA患者的病程。一名患有RA的台湾女性接受了依那西普治疗。由于先前未识别的HBV携带者状态，在开始使用生物制剂后不久，肝脏生化指标严重恶化。通过口服拉米夫定治疗，病情成功缓解。在HBV流行地区，对于开始使用生物制剂等新治疗方式的RA患者，监测病毒载量和进行预防性抗病毒治疗对于避免HBV再激活的严重并发症可能至关重要。